CaMKIIδ Inhibitors

The class of CaMKIIδ inhibitors comprises a diverse array of chemicals designed to either directly antagonize the kinase or indirectly modulate its activity through intricate signaling pathways. KN-93, an exemplary direct inhibitor (CAS Number: 139298-40-1), specifically targets CaMKIIδ by binding to its calmodulin-binding domain, preventing autophosphorylation, and hindering its kinase activity. AIP (CAS Number: 138047-89-3), another direct inhibitor, mimics the autoinhibitory domain of CaMKII, competitively impeding substrate interaction and offering insights into the intricate regulation of CaMKIIδ. Beyond direct inhibition, compounds like H89 (CAS Number: 130964-39-5) exemplify the indirect modulation of CaMKIIδ by targeting the cAMP/PKA pathway.

By inhibiting PKA, H89 influences phosphorylation events that can impact CaMKIIδ, revealing the intricate crosstalk between signaling pathways. Nifedipine (CAS Number: 21829-25-4), a calcium channel blocker, represents an indirect inhibitor altering calcium dynamics to impact CaMKIIδ activation, emphasizing the role of calcium signaling in regulating kinase activity. The versatility of this class is further highlighted by compounds like Staurosporine (CAS Number: 62996-74-1), a broad-spectrum kinase inhibitor, impacting CaMKIIδ indirectly by affecting multiple kinase pathways. TBB (CAS Number: 548472-68-0), a CK2 inhibitor, showcases indirect modulation by altering phosphorylation events through the CK2 signaling axis.